Kim N. Chi, MD, presented “TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer” for the Grand Rounds in Urology audience in September, 2019.

How to cite: Chi, Kim N. “TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer” September, 2019. Accessed Oct 2019. https://grandroundsinurology.com/titan-study-leads-to-fda-approval-of-apalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer/

 TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer – Summary:

Kim N. Chi, MD, and E. David Crawford, MD, discuss the findings of the TITAN study regarding the use of apalutamide in patients with castration-sensitive prostate cancer (mCSPC) who are also undergoing androgen deprivation therapy (ADT). Dr. Chi served as principal investigator on this trial and lead author of the article published in The New England Journal of Medicine. These findings led to the FDA approval of apalutamide for these patients on September 17, 2019. The results showed a significant reduction in radiographic progression or death and a reduction in overall risk of death, and therefore support the addition of apalutamide to ADT for a broad range of patients with mCSPC. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.